Response to Hydroxyurea in a Patient With Sickle Cell Hepatopathy : A Case Report
Copyright © 2021, Safhi et al..
Sickle cell hepatopathy is an underreported entity lacking clear management guidelines. This case highlights the potential role of hydroxyurea (HU) in improving the hepatic dysfunction seen among patients with sickle cell disease (SCD). We herein present the clinical course of a patient prior to and after the initiation of hydroxyurea with an emphasis on long-term outcomes and the patterns of liver injury over a 15-year time course.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Cureus - 13(2021), 12 vom: 27. Dez., Seite e20649 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Safhi, Maha A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 04.01.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7759/cureus.20649 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335120261 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335120261 | ||
| 003 | DE-627 | ||
| 005 | 20231225225136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7759/cureus.20649 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335120261 | ||
| 035 | |a (NLM)34976545 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Safhi, Maha A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response to Hydroxyurea in a Patient With Sickle Cell Hepatopathy |b A Case Report |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.01.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021, Safhi et al. | ||
| 520 | |a Sickle cell hepatopathy is an underreported entity lacking clear management guidelines. This case highlights the potential role of hydroxyurea (HU) in improving the hepatic dysfunction seen among patients with sickle cell disease (SCD). We herein present the clinical course of a patient prior to and after the initiation of hydroxyurea with an emphasis on long-term outcomes and the patterns of liver injury over a 15-year time course | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a exchange blood transfusions | |
| 650 | 4 | |a hydroxyurea | |
| 650 | 4 | |a sickle cell disease | |
| 650 | 4 | |a sickle cell intrahepatic cholestasis | |
| 650 | 4 | |a sickle hepatopathy | |
| 700 | 1 | |a Baghdadi, Rana M |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Marzouki, Adel F |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Sayes, Fatin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cureus |d 2013 |g 13(2021), 12 vom: 27. Dez., Seite e20649 |w (DE-627)NLM24118083X |x 2168-8184 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:12 |g day:27 |g month:12 |g pages:e20649 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7759/cureus.20649 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 12 |b 27 |c 12 |h e20649 | ||